•
Sep 30, 2022

BD Q4 2022 Earnings Report

BD reported mixed Q4 2022 results with a decrease in revenue but an increase in EPS, driven by base revenue growth and strategic execution.

Key Takeaways

BD reported Q4 revenue of $4.761 billion, a decrease of 1.8% as reported, but an increase of 2.3% on a currency-neutral basis. The revenue performance was driven by a base revenue growth of 4.2% as reported, and 8.6% currency-neutral. GAAP diluted EPS was $0.92 and adjusted diluted EPS was $2.75. The company issued FY23 guidance and announced its 51st consecutive year of dividend increases, raising the dividend by 4.6%.

Q4 revenue decreased by 1.8% as reported, but increased by 2.3% on a currency-neutral basis.

Base revenue growth was 4.2% as reported and 8.6% on a currency-neutral basis.

GAAP diluted EPS was $0.92, while adjusted diluted EPS was $2.75.

FY23 revenue is expected to be in the range of $18.6 billion to $18.8 billion.

Total Revenue
$4.76B
Previous year: $5.14B
-7.3%
EPS
$2.75
Previous year: $2.59
+6.2%
Base Revenue Growth
4.2%
Gross Profit
$2.08B
Previous year: $2.29B
-9.2%
Cash and Equivalents
$1.01B
Previous year: $2.28B
-55.9%
Total Assets
$52.9B
Previous year: $53.9B
-1.7%

BD

BD

BD Revenue by Segment

Forward Guidance

The company expects fiscal year 2023 revenues to be in the range of approximately $18.6 billion to $18.8 billion and adjusted diluted EPS to be $11.85 to $12.10.

Positive Outlook

  • Revenue guidance assumes base business currency-neutral revenue growth of 5.25% to 6.25%.
  • Base business revenue guidance reflects continued momentum as we execute our BD 2025 growth strategy.
  • Base business revenue guidance includes an anticipated impact of approximately 100 basis points from an acceleration of our simplification and RECODE programs related to planned strategic portfolio exits.
  • This impact is expected to be fully offset by the positive contribution of approximately 100 basis points from the full-year benefit of recent acquisitions, primarily Parata Systems.
  • The company expects adjusted diluted EPS growth of approximately 9% to 11% on a currency-neutral basis.

Challenges Ahead

  • Revenue guidance assumes approximately $125 to $175 million in COVID-19-only diagnostic testing revenues.
  • Foreign exchange would represent a reduction of approximately 450 basis points to total company revenue growth.
  • This includes an estimated impact from foreign currency of approximately 420 basis points based on current rates.
  • The company's expected adjusted diluted EPS for fiscal 2023 excludes potential charges or gains that may be recorded during the fiscal year.
  • The impact and timing of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.

Revenue & Expenses

Visualization of income flow from segment revenue to net income